Bought-and-paid-for optionality: the company already holds a second, unmonetized position it can switch on at will
The model's full reasoning — Q2 2022 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了一个公司已经拥有的、目前未产生收入或贡献很少的第二项资产,并且管理层正在积极决定如何以及何时将其转化为收入,且这一决定主要在公司自己控制范围内。 在记录中,管理层多次提到“Population Health”和“SelectRx”作为亮点。具体来说: - Tim Danker说:“our population health initiative in SelectRx in particular, have been a bright spot for us. We continue to see strong consumer need and demand for a growing array of health care services we coordinate with the population health platform. Consumer interest in our SelectRx pharmacy solution, in particular, continues to ramp up. To date, we have completed over 40,000 gross customer enrollments, and we are beginning to hit our stride in terms of shipments and recently at list 10,000 active members receiving prescriptions.” - Raffaele Sadun在Slide 14上详细介绍了SelectRx的进展,说“we are more excited than ever about the high level of consumer interest in and demand for the pharmacy services we offer.” 并提到“as of January 31, we've already enrolled over 40,000 new members into our SelectRx offering.” 以及“we now have over 10,000 active paying customers on the SelectRx platform.” 还提到“we remain confident with our forecast to exit this fiscal year with around 25,000 active paying SelectRx members, over 10x what we started the year with.” - 管理层还提到,SelectRx是“a bright spot”和“Population Health initiatives”的一部分,并且他们计划“provide regular updates on our SelectRx membership and revenues.” - 在战略部分,Tim Danker说:“SelectQuote's real value and potential exists beyond just Medicare Advantage.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| LEGH | Legacy Housing Corporation | Q4 2023 | 2024-03-18 | C |
| DM | Desktop Metal, Inc. | Q2 2022 | 2022-08-08 | F |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| CLMT | Calumet Specialty Products Partners, L.P | Q1 2018 | 2018-05-16 | C+ |
| UPLD | Upland Software, Inc. | Q4 2017 | 2018-03-08 | C+ |
| FCX | Freeport-McMoRan Inc. | Q3 2017 | 2017-10-25 | D |
CLMT · Q1 2018 → YESThe question is about whether management describes an already possessed second, largely unmonetized position that they can switch on themselves. YES The transcript shows management describing the Biosynthetic Technologies acquisition as a real holding already in hand (completed Q1 2018, with 71 issued patents, 76 pending, exclusive USDA license), separate from the operations generating current results. It contributes little today (only $4M acquisition expenses noted, no revenue yet), and management is actively deciding how and when to monetize it—via low-capex proof-of-concept at the Missouri esters plant, new product innovation center, and third-party involvement—within their control. This fits the criteria as a dormant capability they are now sequencing for revenue.
LEGH · Q4 2023 → YESThe question is about whether management describes a second, largely unmonetized position that the company already possesses, whose future use is largely within their control, and they're actively dec...YES The transcript shows management describing land holdings as a second, largely unmonetized position separate from current operations. They hired a dedicated team to prioritize and accelerate land development, with Del Val Bastrop County as the top priority, and note capital is accelerating for this project.
FCX · Q3 2017 → YESThe question is about whether management describes a second, largely unmonetized position that they already possess, whose future use is within their control, and they're actively deciding how and whe...YES The transcript shows management describing exactly this situation: the company already owns large undeveloped sulfide resources (Lone Star oxide/sulfide, El Abra sulfide, Kisanfu cobalt, additional Grasberg material) that are not part of current production and contribute little to today's results.